C eliac disease (CD) is an autoimmune disease that affects approximately 1% of the US population and amounts to a substantial public health burden. [1] [2] [3] Symptomatic (diagnosed) CD can be a devastating disease and is associated with increased mortality and substantial accumulated morbidity. 2, 4 Until recently, most of what we knew about CD was based on studies of diagnosed CD. Although an increase in CD is documented worldwide, 2, [5] [6] [7] we have found that even with modern clinical laboratory techniques of CD detection widely available, more than 80% of patients with CD remain undetected clinically. 3, 8 The gluten-free diet (GFD) is mainly considered to be the treatment for glutenrelated conditions including CD and wheat allergy, 4 but was not widely used previously for other disorders. However, several studies [9] [10] [11] found that many people without CD are interested in following a GFD. The benefits of following a GFD in people without CD have not been tested rigorously, and indeed nutritional concerns have been raised about deficient iron, calcium, and fiber consumption. 12, 13 In contrast to public interest in following a GFD, it remains uncertain whether there is any benefit of following a GFD for people without gluten-related conditions. 14 Nonetheless, recent public attention to the GFD has increased dramatically along with the market shares of nutraceutical products. 3, 10, 11, [15] [16] [17] [18] [19] However, the real magnitude of this emerging public health issue and population-based prevalence of gluten-related conditions, including CD and people without celiac disease avoiding gluten (PWAG), are largely unknown in the United States. Many health claims have been based on market researchedirected surveys that may have inherent selection bias, such as polling in shopping malls, or may have covered a short duration. 16, 17, 20 Thus, the objectives of this study were to estimate the prevalence of CD and PWAG and to investigate trends in the prevalence of gluten-related occurrence including CD and PWAG using the data of the 2009 to 2014 National Health and Nutrition Examination Surveys (NHANES).
PATIENTS AND METHODS

National Health and Nutrition Examination Survey Background
The NHANES is designed and conducted to evaluate the health and nutritional status of the US population. [21] [22] [23] The NHANES accurately represents the noninstitutionalized US civilian population because of its complex, stratified, multistage, probability-based sampling design. Approximately 5000 persons per year were recruited to collect information on health and nutritional status by standardized household interviews, physical examinations, and testing of biological samples. [21] [22] [23] More detailed information on the survey design for the NHANES and methods to evaluate CD and PWAG using gluten-related questions and CD laboratory testing is available in our previous publications. 3, 8 Since 1999, the NHANES has been conducted in 2-year cycles continuously and oversampled non-Hispanic blacks, Hispanics, Asians (2011-2014), lowincome whites, and persons aged 80 years or older.
Laboratory Tests for CD
Starting with the NHANES 2009 to 2010, we designed study components to estimate the prevalence of CD and PWAG in the US population. Serologic testing for CD was performed at Mayo Clinic, and 2 structured questions related to the diagnosis of CD and the status of the GFD were asked. The methods for CD serologic testing have been described in detail elsewhere. 3, 8 Briefly, serum samples from 2009 to 2014 NHANES participants aged 6 years or older were collected and shipped to the Celiac Disease Research Laboratory at Mayo Clinic, Rochester, Minnesota. Sequential serologic testing was used to detect CD, which we have found to be an effective method to detect undiagnosed cases in the general population. 24, 25 The human recombinant tissue transglutaminase (tTG)ebased enzyme-linked immunosorbent assay (Inova Diagnostics) was used to measure titers of tTG IgA. 3, 26 If tTG IgA titers were 4.0 U/mL or higher, then sequential testing with IgA endomysial antibody (EMA) was performed by indirect immunofluorescence using the reticulin component of the endomysium of the smooth muscle in monkey esophagus tissue (Inova Diagnostics). 26 The serological diagnosis of CD was based on the double positivity (positive to tTG IgA and subsequent EMA confirmation), which has previously exhibited high sensitivity and specificity. [26] [27] [28] Continuous NHANES 2009 to 2014 For this analysis, data from NHANES 2009 to 2010, 2011 to 2012, and 2013 to 2014 were used. Of a total of 25,547 participants aged 6 years or older between 2009 and 2014, 844 persons who did not receive a health examination were excluded. Our analysis sample comprised a total of 22,277 participants to estimate the prevalence of CD or PWAG after 2426 individuals who were not tested for CD serology or did not respond to CD-related questions were also excluded. The flowchart for the analysis sample is shown in Figure 1 .
The following definitions were adapted from our previous studies 3, 8 ; CD was confirmed if individuals had double positivity (tTG IgA and EMA) or a participant-reported clinical diagnosis of CD. The responses to the following 2 CD-related questions were used to define a reported clinical diagnosis of CD and PWAG: (1) "Has a doctor or other health professional ever told you that you have celiac disease, also called sprue?" and (2) "Are you on a gluten-free diet?" Although a reported clinical diagnosis of CD was defined by positive responses to these 2 questions, PWAG was identified if the individual adhered to a GFD without a health professional's diagnosis of CD and was tested negative on serologic testing.
Statistical Analyses
All statistical analyses followed the National Center for Health Statistics analytic guidelines, which incorporated the effect of complex study design and used appropriate published weights. Statistical analyses were performed using SAS version 9.4 software (SAS Institute). All estimates of prevalence of CD and PWAG were based on weighted data. In addition, a complex study design of oversampling and nonparticipation in the household interview and physical examination and for the changing sampling strategies or priorities over each biennium was incorporated in all analyses. The prevalence of CD, undiagnosed CD, or PWAG from 2009 to 2014 was estimated in the total population, as well as by race (whites, blacks, and Hispanics), children and adults, and sex, if the number of cases was 20 or higher. Trend analyses of the prevalence of CD, undiagnosed CD, or PWAG were performed in the 3 study periods, that is, 2009 to 2010, 2011 to 2012, and 2013 to 2014, using the chi-square test. P values less than .05 were considered statistically significant.
RESULTS
Overall Prevalence of CD in NHANES 2009 to 2014
Of 22,277 individuals aged 6 years or older from 2009 to 2014 NHANES, 39% were non-Hispanic white (n¼8652), 22% nonHispanic black (n¼4825), 27% Hispanic (n¼6098), and 12% were other race groups including Asians (n¼2702). Based on serological or clinical diagnosis, CD was confirmed in 109 participants. In participants Although it was similar among racial and ethnicity groups, the prevalence of PWAG was significantly higher (P¼.006) in women than in men (Table) . 
DISCUSSION
In recent years, public attention to glutenrelated conditions, including CD and the practice of avoiding gluten in the diet, has increased dramatically, reflecting the marked growth of the gluten-free food industry. 16, 20 Many studies 3, 6, 29 from Western countries found that the prevalence of CD is increasing recently, reflecting not only advances in serologic testing but also increased awareness of CD in the general public and physicians. In the present study, we reported that the overall prevalence of CD in the United States remained stable from 2009 to 2014. Interestingly, the prevalence of undiagnosed CD decreased significantly in this period, suggesting a success in detection, an increased awareness of CD, or maybe an increasing preference for a GFD. During this same period, the prevalence of PWAG more than tripled, increasing to an estimated 3.1 million persons. In the past, CD was a rare disorder in the United States, measuring 1 in 652 persons from a military cohort in the 1950s. 2 However, the prevalence of CD in the world has increased dramatically. 3, 6, 29, 30 In our previous nationally representative US study, 3 we reported that the prevalence of CD in adults aged 50 years or older more than doubled between 1988 and 2012. Indeed, this trend is similar to that found in other Western countries, in which the overall prevalence of CD is on the rise. 6, 29, 31 The present study found stable CD prevalence in the US population over a recent 6-year period. This may represent a true leveling in prevalence or too short of a period to see a change in prevalence. The recent decrease in the prevalence of undiagnosed CD suggests an increased awareness of the disease in the general public and health care professionals. However, this finding should be cautiously interpreted because the number of undiagnosed CD cases is small and the prevalence decreased only in the last 2-year cycle. Another possible explanation for the decreased prevalence of undiagnosed CD is that positive results of serologic CD testing may be influenced by the increased proportion of people following a GFD in the US population. However, further studies of the relationship between CD and the public perception of gluten-free foods as a healthier dietary option are needed. It is also possible that persons who become symptomatic from undiagnosed CD may try a GFD empirically without testing, thereby moving into the PWAG group. Future epidemiology studies, including serological surveys, will need to take into account this secular trend toward gluten avoidance.
As expected, racial disparity in the prevalence of CD was observed in the present study; most CD cases (75 of 109) were among nonHispanic whites. Of 4826 non-Hispanic blacks, only 6 cases met the CD diagnosis, which was about 1 in 804 people. Consistent with other studies of sex differences, the present study found that the prevalence of CD is higher in women than in men. Interestingly, the prevalence of undiagnosed CD was similar between women and men. Differences in health risk behavior in men and women may partly affect the sex difference in the prevalence of diagnosed and undiagnosed CD. Another interesting finding about CD prevalence is the difference between children and adults. In contrast to other studies 30, 32, 33 that have reported a higher CD prevalence in children than in adults, we found that the prevalence of CD was similar between children aged 6 to 18 years and adults. This difference between studies may be due to population selection or small sample size of previous studies, most of which were conducted in selected populations from referral centers. 32, 33 We found a steady increase in the proportion of people following a GFD from 2009 to 2014. Interestingly, this increasing trend was predominantly in people who did not have a diagnosis of CD and more than tripled from 0.5% in NHANES 2009 to 2011 to 1.7% in NHANES 2013 to 2014. Although the reasons why people choose to follow a GFD are unclear, the trend of more people choosing a GFD is significant in the NHANES. Several surveys, 16, 17, 20 including market research, Gallup, and consumer reports, found that more than 20% of Americans seek glutenfree products. These polls have several limitations including selection bias, low response .005
CD on a GFD PWAG EPIDEMIOLOGY OF CELIAC DISEASE AND GLUTEN AVOIDANCE rate, and inadequate validity. In contrast, the present study using the NHANES, a robust and representative sample of the US general population with direct interview responses to gluten-and CD-related questions, seems to most likely reflect the actual prevalence and trends of the GFD in the United States. The health or nutritional benefits of a GFD in people without CD and/or wheat allergy have not been rigorously tested and hence are unproven. Rather, several studies 34-37 raised nutritional concerns in people following a GFD, such as high fat and sugar consumption, micronutrient deficiency, and induction of the metabolic syndrome. In contrast to these studies, DiGiacomo et al 19 reported a slightly better cardiometabolic profile including normal weight and higher high-density lipoproteinecholesterol level in individuals without CD following a GFD. Thus, further studies of PWAG are warranted to evaluate the association with clinical deterioration, similarities to CD, and social and economic burdens.
The present study has several limitations. With regard to CD diagnosis, serology may not detect persons with CD and IgA deficiency. However, very few people with undiagnosed CD should have been missed in the present study because of the low prevalence of selective IgA deficiency. Although the present study did not confirm the diagnosis of CD by intestinal biopsy, double sequential serologic testing to detect undiagnosed CD had been validated in our laboratory and others before the present study using NHANES was designed. 24, 25, 38 Moreover, this study applied a highly sensitive and specific serologic testing and interview questions to a representative US population; the NHANES provided us the opportunity for an unbiased study of the epidemiology of gluten-related conditions, including CD and GFD, in the US population. We did not ask participants why they chose a GFD, so it is possible that some persons with undetected CD had started following a GFD and thereby were incorrectly assigned to the PWAG group. One survey 11 in Australia found that 80% of people who reported avoiding wheat had experienced at least 1 negative reaction to the consumption of wheat-based products. In addition, Biesiekierski et al 39 reported that 3 in 4 individuals with self-reported nonceliac gluten sensitivity had symptom improvement from avoiding gluten.
CONCLUSION
The present study, which was based on the US representative population, found that the prevalence of CD remained stable from 2009 to 2014, but the prevalence of undiagnosed CD decreased significantly in this period. This trend was more prominent in nonHispanic whites and adults. Remarkably, the proportion of individuals maintaining a GFD in the absence of a diagnosis of CD increased markedly in this period. In light of this increasing trend in the use of a GFD, the clinical consequences of the GFD require further investigation.
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